Article (Scientific journals)
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease.
Scheen, André
2017In Evidence-Based Medicine
Peer Reviewed verified by ORBi
 

Files


Full Text
2017 ebm comment empagliflozin.pdf
Publisher postprint (320.27 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
CLINICAL PHARMACOLOGY
Disciplines :
Cardiovascular & respiratory systems
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège > Département des sciences cliniques > Département des sciences cliniques
Language :
English
Title :
SGLT2 inhibitor empagliflozin reduces renal outcomes and dampens the progressive reduction in glomerular filtration rate in patients with type 2 diabetes and antecedents of cardiovascular disease.
Publication date :
2017
Journal title :
Evidence-Based Medicine
ISSN :
1356-5524
eISSN :
1473-6810
Publisher :
BMJ Publishing Group, United Kingdom
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 24 March 2017

Statistics


Number of views
66 (5 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
1
Scopus citations®
without self-citations
1
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi